{
    "code": "02021157",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02021157",
    "time": "2021-12-24 03:18:01",
    "許可證字號": "衛署藥輸字第021157號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/02\/15",
    "發證\/登錄日期": "110\/01\/11",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202115704",
    "中文品名": "汰癌勝注射液（派立達師）",
    "英文品名": "TAXOL (PACLITAXEL) INJECTION 30MG\/5ML",
    "適應症": "晚期卵巢癌、腋下淋巴轉移之乳癌，作為接續含杜薩魯比辛（DOXORUBICIN）在內之輔助化學療法、已使用合併療法（除非有禁忌，至少應包括使用ANTHRACYCLINE抗癌藥）失敗的轉移乳癌、非小細胞肺癌、愛滋病相關卡波西氏肉瘤之第二線療法；與CISPLATIN併用，作為晚期卵巢癌之第一線療法。與GEMCITABINE併用，可使用於曾經使用過ANTHRACYCLINE之局部復發且無法手術切除或轉移性之乳癌病患、與HERCEPTIN併用時，用於治療未接受過化學治療之轉移性且乳癌過度表現HER-2之病人。",
    "劑型": "270注射劑",
    "包裝": "5,16.7,50公撮小瓶裝 各100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "92\/02\/15",
    "主成分略述": "PACLITAXEL",
    "限制項目": "02輸　入",
    "申請商名稱": "1404501100  台灣必治妥施貴寶股份有限公司",
    "申請商地址": "台北市松山區健康路156號4樓、5樓",
    "主製造廠": [
        {
            "": "ITALY",
            "製程": ""
        }
    ],
    "CCC號列": "30049071005 抗癌藥Anti-cancer preparations",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000100",
            "成分名稱": "PACLITAXEL",
            "含量描述": "",
            "含量": "30.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "紙盒尺寸: 長*寬*高 52 X 42 X 72 mm",
        "特殊劑型": "",
        "顏色": "清澈、無色至接近淡黃",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "衛署藥輸字第021157號 汰癌勝注射液(派立達師) 藥品外觀-108-03-28(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021157&Seq=003&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "05c 20211103-taxol-tw-lft appr v1.0-110-11-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021157&Seq=015&Type=9"
        },
        {
            "title": "05b 20211103-taxol-tw-lbl appr v1.0-110-11-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021157&Seq=006&Type=8"
        },
        {
            "title": "05a 20211103-taxol-tw-ctn appr v1.0-110-11-10.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02021157&Seq=005&Type=8"
        }
    ]
}